Head-to-head comparisons
Popular matchups
- Semaglutide vs tirzepatide
Two leading GLP-1 therapies for obesity and type 2 diabetes
- Cagrilintide vs tirzepatide
A GLP-1/amylin combination against a GLP-1/GIP dual agonist
- Orforglipron vs semaglutide
An oral GLP-1 candidate against an injectable GLP-1 standard
- Retatrutide vs tirzepatide
A triple agonist against a dual agonist in metabolic disease
- Donanemab vs lecanemab
Two anti-amyloid antibodies for early Alzheimer's disease
- Olezarsen vs pelacarsen
Two RNA-targeted therapies for lipid and Lp(a) lowering
- Adagrasib vs sotorasib
Two KRAS G12C inhibitors in solid tumours
- Nivolumab vs pembrolizumab
Two PD-1 checkpoint inhibitors in oncology
- Sacituzumab govitecan vs trastuzumab deruxtecan
Two antibody-drug conjugates in solid tumours
- Risankizumab vs upadacitinib
Two therapies for immune-mediated inflammatory disease
GLP-1 & incretin therapies
Metabolic
- semaglutide (Ozempic / Wegovy)
View trial timeline
- tirzepatide (Mounjaro / Zepbound)
View trial timeline
- orforglipron
View trial timeline
- retatrutide
View trial timeline
- survodutide
View trial timeline
- mazdutide
View trial timeline
- cagrilintide
View trial timeline
- dulaglutide (Trulicity)
View trial timeline
- liraglutide (Victoza / Saxenda)
View trial timeline
Cardiometabolic & renal
Metabolic
MASH / liver disease
Metabolic
Lipid & Lp(a) therapies
Cardiovascular
Cardiomyopathy & ATTR amyloidosis
Cardiovascular
Immuno-oncology checkpoint inhibitors
Oncology
Antibody-drug conjugates
Oncology
KRAS inhibitors
Oncology
Targeted & bispecific oncology
Oncology
Immunology & inflammation
Immunology
Neuroscience
Neuroscience
Women's health
Women's health
Respiratory
Respiratory
